Portola CEO Homcy to retire from post; OXiGENE raises cash for cancer trial

@FierceBiotech: Biotech VCs, Big Pharma stepping outside the comfort zone. Article | Follow @FierceBiotech

@JohnCFierce: Either Facet's assets are very valuable or they're worthless. If Biogen saw that there was value enough to warrant a bid, why lowball it?  Follow @JohnCFierce

> Dr. Charles Homcy says he will retire as CEO from Portola Pharmaceuticals, stepping into a new role as co-chairman of the developer. Chief Operating Officer William Lis will succeed Dr. Homcy as the new CEO. Homcy has been CEO for seven years. Release

> OXiGENE says it has raised $7.5 Million in financing. The money will be used for the developer's cancer programs, including its ongoing trials of Zybrestat in non-small cell lung cancer and of OXi4503 trials in solid tumors. Release

> Neurologix announced that Clark A. Johnson, the vice chairman, has been appointed as president and CEO to replace John E. Mordock, who resigned. Release

> Cel-Sci has received a $125,000 check from Byron Biopharma from a deal that gives Byron marketing rights of the biotech's lead drug in South Africa. Report

And Finally... A newly discovered ability for people to taste fat could hold the key to reducing obesity, Deakin University health researchers believe. Release

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.